Last reviewed · How we verify
E-Aminocaproic acid
E-Aminocaproic acid is a Small molecule drug developed by Hospital for Special Surgery, New York. It is currently FDA-approved. Also known as: EACA.
E-Aminocaproic acid is used to reduce blood loss and transfusion requirements after bilateral varus rotational osteotomy. It is administered intravenously for this purpose.
At a glance
| Generic name | E-Aminocaproic acid |
|---|---|
| Also known as | EACA |
| Sponsor | Hospital for Special Surgery, New York |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E-Aminocaproic acid CI brief — competitive landscape report
- E-Aminocaproic acid updates RSS · CI watch RSS
- Hospital for Special Surgery, New York portfolio CI
Frequently asked questions about E-Aminocaproic acid
What is E-Aminocaproic acid?
Who makes E-Aminocaproic acid?
Is E-Aminocaproic acid also known as anything else?
What development phase is E-Aminocaproic acid in?
Related
- Manufacturer: Hospital for Special Surgery, New York — full pipeline
- Also known as: EACA
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing